CY1109129T1 - Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους - Google Patents

Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους

Info

Publication number
CY1109129T1
CY1109129T1 CY20091100582T CY091100582T CY1109129T1 CY 1109129 T1 CY1109129 T1 CY 1109129T1 CY 20091100582 T CY20091100582 T CY 20091100582T CY 091100582 T CY091100582 T CY 091100582T CY 1109129 T1 CY1109129 T1 CY 1109129T1
Authority
CY
Cyprus
Prior art keywords
compound
naphthyridin
isoindolinone
prodrug
chloro
Prior art date
Application number
CY20091100582T
Other languages
English (en)
Inventor
Cathyrn Montgomery Clary
Sean David Donevan
Perry Steven Eisman
Richard J Kavoussi
Lyou-Fu Ma
Beek Jeroen Bernard Van
Atul Chandra Pande
Original Assignee
Indevus Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indevus Pharmaceuticals, Inc. filed Critical Indevus Pharmaceuticals, Inc.
Publication of CY1109129T1 publication Critical patent/CY1109129T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους και τυποποιημένες συσκευασίες (kits) για θεραπεία της διαταραχής κοινωνικού άγχους, με χρήση μιας ένωσης που είναι 2-(7-χλωρο-1,8-ναφθυριδιν-2-υλ)-3-(5-μεθυλο-2-οξο-εξυλο)-1 -ισοϊνδολινόνη ή 2-(7-χλωρο-1,8- ναφθυριδιν-2-υλ)-3-(5-μεθυλο-5-υδροξυ-2-οξοεξυλο)-1- ισοϊνδολινόνη ή ένα φαρμακευτικώς αποδεκτό άλας, οπτικό ισομερές ή προφάρμακο αυτής. Η παρούσα εφεύρεση επίσης παρέχει σκευάσματα που περιέχουν την αναφερόμενη ένωση ή ένα φαρμακευτικώς αποδεκτό άλας οπτικό ισομερές ή προφάρμακο αυτής και μια επιπλέον ένωση που είναι χρήσιμη για τη θεραπεία των καταστάσεων που προαναφέρθηκαν.
CY20091100582T 2001-04-30 2009-06-01 Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους CY1109129T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28754501P 2001-04-30 2001-04-30
EP05028364A EP1642576B1 (en) 2001-04-30 2002-04-16 Use of pyrrole derivatives to combat anxiety

Publications (1)

Publication Number Publication Date
CY1109129T1 true CY1109129T1 (el) 2014-07-02

Family

ID=23103396

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100582T CY1109129T1 (el) 2001-04-30 2009-06-01 Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους

Country Status (21)

Country Link
US (2) US7026332B2 (el)
EP (2) EP1254660B1 (el)
JP (1) JP2002326934A (el)
KR (1) KR20020084413A (el)
CN (1) CN1384104A (el)
AT (2) ATE424820T1 (el)
AU (1) AU783516B2 (el)
CA (1) CA2383599C (el)
CY (1) CY1109129T1 (el)
DE (2) DE60231568D1 (el)
DK (1) DK1642576T3 (el)
ES (2) ES2267943T3 (el)
HK (1) HK1094307A1 (el)
HU (1) HU228826B1 (el)
IL (2) IL149280A0 (el)
MY (1) MY129575A (el)
NZ (1) NZ518615A (el)
PL (2) PL207725B1 (el)
PT (1) PT1642576E (el)
TW (1) TWI302455B (el)
ZA (1) ZA200203347B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012392A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamientos de ansiedad con ziprasidona.
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
RU2006107534A (ru) * 2003-09-12 2007-09-20 Уорнер-Ламберт Компани Ллс (Us) Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства
CN1849153A (zh) * 2003-09-12 2006-10-18 辉瑞大药厂 含有α－2－δ配体和5－羟色胺/去甲肾上腺素重摄取抑制剂的组合物
US20050232983A1 (en) * 2004-04-14 2005-10-20 Indevus Pharmaceuticals, Inc. Transdermal patch
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2678337A1 (en) * 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
AU2020241731B2 (en) * 2019-03-18 2023-09-07 Neurocycle Therapeutics, Inc. Use of GABAA receptor modulators for treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607503B1 (fr) 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) 1988-04-26 1989-11-09 Davy Mckee Ag Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (en) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
FR2678932B1 (fr) 1991-07-12 1993-09-24 Rhone Poulenc Rorer Sa Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2678934B1 (fr) 1991-07-12 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2681068B1 (fr) 1991-09-09 1993-11-19 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr) 1991-12-04 1994-01-21 Rhone Poulenc Rorer Sa Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr) 1992-09-08 1994-11-04 Rhone Poulenc Rorer Sa Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) * 1994-01-12 1996-03-12 Rhone-Poulenc Rorer S.A. 2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) * 1996-03-29 1997-04-23 Lilly Co Eli Treatment of obsessive-compulsive disorder
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function

Also Published As

Publication number Publication date
DE60231568D1 (de) 2009-04-23
EP1254660B1 (en) 2006-06-28
HU228826B1 (en) 2013-05-28
CA2383599C (en) 2006-10-31
IL149280A0 (en) 2002-11-10
EP1254660A2 (en) 2002-11-06
ATE424820T1 (de) 2009-03-15
EP1642576B1 (en) 2009-03-11
JP2002326934A (ja) 2002-11-15
DK1642576T3 (da) 2009-04-14
AU2760902A (en) 2002-10-31
PL353681A1 (en) 2002-11-04
TWI302455B (en) 2008-11-01
IL204665A (en) 2011-05-31
PT1642576E (pt) 2009-05-21
ES2323646T3 (es) 2009-07-22
EP1642576A2 (en) 2006-04-05
KR20020084413A (ko) 2002-11-07
ZA200203347B (en) 2003-11-26
AU783516B2 (en) 2005-11-03
MY129575A (en) 2007-04-30
HK1094307A1 (en) 2007-03-30
PL207725B1 (pl) 2011-01-31
US7026332B2 (en) 2006-04-11
EP1642576A3 (en) 2007-01-10
ATE331513T1 (de) 2006-07-15
US7553847B2 (en) 2009-06-30
CN1384104A (zh) 2002-12-11
HUP0201394A3 (en) 2003-12-29
HU0201394D0 (el) 2002-06-29
US20030022915A1 (en) 2003-01-30
US20060128746A1 (en) 2006-06-15
NZ518615A (en) 2004-03-26
DE60212757D1 (de) 2006-08-10
HUP0201394A2 (hu) 2002-12-28
EP1254660A3 (en) 2003-03-26
PL207738B1 (pl) 2011-01-31
PL390683A1 (pl) 2010-05-24
DE60212757T2 (de) 2007-06-28
ES2267943T3 (es) 2007-03-16
CA2383599A1 (en) 2002-10-30

Similar Documents

Publication Publication Date Title
CY1109129T1 (el) Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
CY1105986T1 (el) Παραγωγα ινδολιου χρησιμα ως ανταγωνιστες η3 ισταμινης
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1111670T1 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
CY1112142T1 (el) Κυκλοπεντα [d] πυριμιδινες ως αναστολεις της κινασης πρωτεϊνης του ακτ
CY1110583T1 (el) Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
CY1107953T1 (el) Ενωσεις υποκαθιστουμενης βενζιμιδαζολης και η χρηση τους για τη θεραπεια του καρκινου
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
CY1108625T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
ATE346067T1 (de) Carbolinderivate
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
CY1110415T1 (el) Πρωτοτυπα παραγωγα τετραϋδροκαρβαζολιου με βελτιωμενη βιολογικη δραση και βελτιωμενη διαλυτοτητα, ως συνδετες για υποδοχεις συζευγμενους με πρωτεϊνη g (gpcrs)
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
AR035247A1 (es) Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
DE60142304D1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen